Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Change in Cash (2016 - 2025)

Historic Change in Cash for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $31.8 million.

  • Amicus Therapeutics' Change in Cash rose 3016.39% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.0 million, marking a year-over-year decrease of 4587.46%. This contributed to the annual value of -$33.4 million for FY2024, which is 13440.63% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Change in Cash of $31.8 million as of Q3 2025, which was up 3016.39% from -$22.7 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Change in Cash peaked at $209.3 million during Q3 2021, and registered a low of -$139.6 million during Q4 2021.
  • For the 5-year period, Amicus Therapeutics' Change in Cash averaged around $1.5 million, with its median value being -$437000.0 (2024).
  • As far as peak fluctuations go, Amicus Therapeutics' Change in Cash surged by 232149.17% in 2023, and later plummeted by 509839.82% in 2025.
  • Over the past 5 years, Amicus Therapeutics' Change in Cash (Quarter) stood at -$139.6 million in 2021, then grew by 8.02% to -$128.4 million in 2022, then surged by 87.39% to -$16.2 million in 2023, then decreased by 24.14% to -$20.1 million in 2024, then soared by 258.39% to $31.8 million in 2025.
  • Its Change in Cash was $31.8 million in Q3 2025, compared to -$22.7 million in Q2 2025 and -$32.0 million in Q1 2025.